Aradigm Corporation Receives Milestone Payment From Novo Nordisk for Development of AERx(R) Diabetes Management System

Apr 05, 2001, 01:00 ET from Aradigm Corporation

    HAYWARD, Calif., April 5 /PRNewswire/ -- Aradigm Corporation
 (Nasdaq: ARDM) today announced that the company has received a milestone
 payment from Novo Nordisk (NYSE:   NVO) in connection with completing certain
 clinical and product development milestones for the development of the AERx
 (R) Diabetes Management System.  Aradigm is developing the AERx System with
 Novo Nordisk to deliver insulin via inhalation for patients with diabetes.
     "Novo Nordisk is pleased to be involved with Aradigm in this project, as
 we believe Aradigm's technology is superior for the pulmonary delivery of
 insulin," said Mads Krogsgaard Thomsen, executive vice president and chief
 science officer at Novo Nordisk.  "This is a significant program for our
 company.  We have completed the pre-clinical safety requirements and are
 preparing for the start of Phase 3 trials."
     Aradigm and Novo Nordisk are in Phase 2 clinical trials with inhaled
 insulin delivered using the AERx Pulmonary Delivery System.  Clinical results
 to date confirm that pulmonary delivery using the AERx System is a
 reproducible method for delivering insulin to the bloodstream that is
 comparable to delivery via subcutaneous administration.
     "This is an important accomplishment for Aradigm," said Richard Thompson,
 chairman, president and CEO of Aradigm.  "We are very excited about this
 program and believe that we have the right non-invasive solution for patients
 who need insulin. For patients with diabetes, pulmonary delivery of insulin
 with the AERx System may offer a quick and effective alternative that could
 dramatically increase their quality of life."
     Aradigm and Novo Nordisk have been collaborating on the development of the
 AERx Diabetes Management System since 1998.  The AERx System uses liquid
 formulated insulin, which allows for low cost manufacturing, and includes
 automatic breath control that assures that patients are breathing in the
 correct manner with each dose of insulin.
     Aradigm is working to improve the quality of life of patients by
 developing aerosol-based drug delivery alternatives to injectable
 therapeutics.  The Company's advanced pulmonary delivery technologies provide
 leading pharmaceutical and biotechnology partners with effective drug delivery
 solutions.  Current development programs focus on diabetes, pain management,
 and the pulmonary delivery of existing and emerging biotech therapeutics.
     Based in Hayward, California, Aradigm is currently developing products for
 diabetes management with Novo Nordisk A/S, the world leader in insulin and
 diabetes care, and breakthrough and acute pain management for GlaxoSmithKline,
 a world leader in oncology therapy and supportive care. In addition, Aradigm
 has four additional partner-funded programs and a gene therapy effort funded
 through the National Institutes of Health. More information about Aradigm can
 be found at www.aradigm.com. Investors may also request company information
 via email by directing inquiries to investor@aradigm.com.
 
     Please note:
     Except for the historical information contained herein, this news release
 contains forward-looking statements that involve risk and uncertainties,
 including the timely availability and acceptance of new products, the impact
 of competitive products and pricing, and the management of growth, as well as
 the other risks detailed from time to time in Aradigm Corporation's Securities
 and Exchange Commission (SEC) Registration Statements, including the company's
 Annual Report on Form 10-K as amended.
 
      Contacts:
      At Aradigm:
      Norman Halleen
      Chief Financial Officer
      (510) 265 9000
 
      For Media and Investors:
      Kari Lampka
      Feinstein Kean Healthcare
      (617) 577 8110
 
 

SOURCE Aradigm Corporation
    HAYWARD, Calif., April 5 /PRNewswire/ -- Aradigm Corporation
 (Nasdaq: ARDM) today announced that the company has received a milestone
 payment from Novo Nordisk (NYSE:   NVO) in connection with completing certain
 clinical and product development milestones for the development of the AERx
 (R) Diabetes Management System.  Aradigm is developing the AERx System with
 Novo Nordisk to deliver insulin via inhalation for patients with diabetes.
     "Novo Nordisk is pleased to be involved with Aradigm in this project, as
 we believe Aradigm's technology is superior for the pulmonary delivery of
 insulin," said Mads Krogsgaard Thomsen, executive vice president and chief
 science officer at Novo Nordisk.  "This is a significant program for our
 company.  We have completed the pre-clinical safety requirements and are
 preparing for the start of Phase 3 trials."
     Aradigm and Novo Nordisk are in Phase 2 clinical trials with inhaled
 insulin delivered using the AERx Pulmonary Delivery System.  Clinical results
 to date confirm that pulmonary delivery using the AERx System is a
 reproducible method for delivering insulin to the bloodstream that is
 comparable to delivery via subcutaneous administration.
     "This is an important accomplishment for Aradigm," said Richard Thompson,
 chairman, president and CEO of Aradigm.  "We are very excited about this
 program and believe that we have the right non-invasive solution for patients
 who need insulin. For patients with diabetes, pulmonary delivery of insulin
 with the AERx System may offer a quick and effective alternative that could
 dramatically increase their quality of life."
     Aradigm and Novo Nordisk have been collaborating on the development of the
 AERx Diabetes Management System since 1998.  The AERx System uses liquid
 formulated insulin, which allows for low cost manufacturing, and includes
 automatic breath control that assures that patients are breathing in the
 correct manner with each dose of insulin.
     Aradigm is working to improve the quality of life of patients by
 developing aerosol-based drug delivery alternatives to injectable
 therapeutics.  The Company's advanced pulmonary delivery technologies provide
 leading pharmaceutical and biotechnology partners with effective drug delivery
 solutions.  Current development programs focus on diabetes, pain management,
 and the pulmonary delivery of existing and emerging biotech therapeutics.
     Based in Hayward, California, Aradigm is currently developing products for
 diabetes management with Novo Nordisk A/S, the world leader in insulin and
 diabetes care, and breakthrough and acute pain management for GlaxoSmithKline,
 a world leader in oncology therapy and supportive care. In addition, Aradigm
 has four additional partner-funded programs and a gene therapy effort funded
 through the National Institutes of Health. More information about Aradigm can
 be found at www.aradigm.com. Investors may also request company information
 via email by directing inquiries to investor@aradigm.com.
 
     Please note:
     Except for the historical information contained herein, this news release
 contains forward-looking statements that involve risk and uncertainties,
 including the timely availability and acceptance of new products, the impact
 of competitive products and pricing, and the management of growth, as well as
 the other risks detailed from time to time in Aradigm Corporation's Securities
 and Exchange Commission (SEC) Registration Statements, including the company's
 Annual Report on Form 10-K as amended.
 
      Contacts:
      At Aradigm:
      Norman Halleen
      Chief Financial Officer
      (510) 265 9000
 
      For Media and Investors:
      Kari Lampka
      Feinstein Kean Healthcare
      (617) 577 8110
 
 SOURCE  Aradigm Corporation